Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) was upgraded by TheStreet from a “c+” rating to a “b” rating in a research note issued to investors on Monday.

Separately, ValuEngine raised shares of Opiant Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, September 6th.

Shares of Opiant Pharmaceuticals (OPNT) opened at 35.78 on Monday. The firm’s 50-day moving average price is $36.56 and its 200 day moving average price is $16.10. The firm has a market capitalization of $72.49 million, a P/E ratio of 13.46 and a beta of -0.97. Opiant Pharmaceuticals has a 12 month low of $5.00 and a 12 month high of $51.90.

Opiant Pharmaceuticals (NASDAQ:OPNT) last announced its quarterly earnings results on Friday, October 13th. The technology company reported ($0.17) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.70. Opiant Pharmaceuticals had a net margin of 35.68% and a return on equity of 278.86%. The firm had revenue of $3.77 million during the quarter. Analysts anticipate that Opiant Pharmaceuticals will post $0.50 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Opiant Pharmaceuticals, Inc. (OPNT) Lifted to “B” at TheStreet” was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this news story on another site, it was copied illegally and republished in violation of international trademark & copyright laws. The legal version of this news story can be read at https://www.watchlistnews.com/opiant-pharmaceuticals-inc-opnt-lifted-to-b-at-thestreet/1638329.html.

About Opiant Pharmaceuticals

Opiant Pharmaceuticals, Inc, formerly Lightlake Therapeutics, Inc, is a specialty pharmaceutical company. The Company develops pharmacological treatments for substance use, addictive and eating disorders. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdoses, which was conceived, licensed, developed and approved by the United States Food and Drug Administration (FDA).

Receive News & Ratings for Opiant Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.